Loading...

 

What is it about?

This review article demonstrates that t-MDS is more similar to de novo MDS than t-AML, and its prognosis should be obtained from the same parameter of de novo MDS. Cytogenetics and mutations are qualitatively the same, but the high-risk mutations and cytogenetics are more frequent in t-MDS.

Featured Image

Why is it important?

The conclusion of this review article is in line with the new classification of myeloid neoplasm, which abolishes the group of therapy-related myeloid neoplasm, including AML and MDS.

Perspectives

GLSorry, your browser does not support inline SVG.

At present the diagnosis of therapy-related MDS is based only on the history of the patient, some other parameter should be added, like some mutations more frequent in the therapy-related.

Prof. Giuseppe Leone
Universita Cattolica del Sacro Cuore

Read the Original

This page is a summary of: DE NOVO AND THERAPY-RELATED MYELODYSPLASTIC SYNDROMES: ANALOGIES AND DIFFERENCES, Mediterranean Journal of Hematology and Infectious Diseases, April 2022, Institute of Hematology, Catholic University,
DOI: 10.4084/mjhid.2022.030.
You can read the full text:

Read

Contributors

The following have contributed to this page